OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study
- 3 November 2022
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 270 (2) , 986-994
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd editionCephalalgia, 2018
- Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysisCephalalgia, 2016
- The International Classification of Headache Disorders, 3rd edition (beta version)Cephalalgia, 2013
- Autonomic nervous system control of the cerebral circulation2013
- Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well‐Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical ProgramHeadache: The Journal of Head and Face Pain, 2010
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialCephalalgia, 2010
- Migraine in the Elderly: A Comparison With Migraine in Young AdultsHeadache: The Journal of Head and Face Pain, 2006
- Preface to the Second EditionCephalalgia, 2004
- Characteristics of Migraine in an Out-Patient Population Over 60 Years of AgeCephalalgia, 2003
- Botulinum toxin type A in the treatment of upper extremity spasticityNeurology, 1996